Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Ceftolozane-tazobactam versus levofloxacin in urinary tract infection

The ASPECT-cUTI trial by Florian Wagenlehner and colleagues1 reported that intravenous ceftolozane-tazobactam was not only non-inferior but also superior to intravenous levofloxacin in the composite of microbiological eradication and clinical cure of complicated urinary tract infections. In view of the increasing rate of bacteria resistant to fluoroquinolones, these findings are not unexpected.2,3 In the Netherlands, recent recommendations by the ISIS-AR study group4 no longer endorse the use of fluoroquinolones as first-line empirical treatment of complicated urinary-tract infections, but suggest initial combination treatment with either amoxicillin or amoxicillin-clavulanic acid, or a second or third generation cephalosporin and an aminoglycoside.